Silvio Garofalo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1177856/publications.pdf

Version: 2024-02-01

623188 794141 1,292 19 14 19 citations g-index h-index papers 19 19 19 1384 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Activation of Statl by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature, 1997, 386, 288-292.	13.7	310
2	Normal long bone growth and development in type X collagen-null mice. Nature Genetics, 1994, 8, 129-135.	9.4	145
3	Characterization of primary cultures of chondrocytes from type II collagen/β-galactosidase transgenic mice. Matrix Biology, 1994, 14, 329-335.	1.5	143
4	Use of a New Rat Chondrosarcoma Cell line to Delineate a 119 -Base Pair Chondrocyte-specific Enhancer Element and to Define Active Promoter Segments in the Mouse Pro- $\hat{l}\pm 1$ (II) Collagen Gene. Journal of Biological Chemistry, 1995 , 270 , 27711 - 27719 .	1.6	139
5	Overexpression of the C-type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation. Human Mutation, 2007, 28, 724-731.	1.1	118
6	Targeted Expression of SHH Affects Chondrocyte Differentiation, Growth Plate Organization, and Sox9 Expression. Journal of Bone and Mineral Research, 2004, 19, 1678-1688.	3.1	100
7	Skeletal Dysplasia and Defective Chondrocyte Differentiation by Targeted Overexpression of Fibroblast Growth Factor 9 in Transgenic Mice. Journal of Bone and Mineral Research, 1999, 14, 1909-1915.	3.1	91
8	Depletion of cartilage collagen fibrils in mice carrying a dominant negative Col2a1 transgene affects chondrocyte differentiation. American Journal of Physiology - Cell Physiology, 2003, 285, C1504-C1512.	2.1	51
9	Inhibition of type 5 phosphodiesterase counteracts \hat{l}^2 2-adrenergic signalling in beating cardiomyocytes. Cardiovascular Research, 2015, 106, 408-420.	1.8	40
10	Specific hybridization probes for mouse $\hat{l}\pm 2(IX)$ and $\hat{l}\pm 1(X)$ collagen mRNAs. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1992, 1130, 78-80.	2.4	27
11	Developmental expression of a type II collagen/ \hat{I}^2 -galactosidase fusion gene in transgenic mice. Developmental Dynamics, 1995, 204, 202-210.	0.8	27
12	Y-Position Collagen II Mutation Disrupts Cartilage Formation and Skeletal Development in a Transgenic Mouse Model of Spondyloepiphyseal Dysplasia. Journal of Bone and Mineral Research, 2002, 17, 39-47.	3.1	25
13	Skeletal development in transgenic mice expressing a mutation at Gly574Ser of type II collagen. Developmental Dynamics, 1997, 208, 170-177.	0.8	24
14	A 47â€bp Sequence of the First Intron of the Mouse Proα1 (II) Collagen Gene Is Sufficient to Direct Chondrocyte Expression. Annals of the New York Academy of Sciences, 1996, 785, 284-287.	1.8	14
15	From Genetics to Genomics of Epilepsy. Neurology Research International, 2012, 2012, 1-18.	0.5	13
16	Transient dimerization and interaction with ERGIC-53 occur in the fibroblast growth factor receptor 3 early secretory pathway. International Journal of Biochemistry and Cell Biology, 2008, 40, 2649-2659.	1.2	9
17	Type II collagen Pro-α-chains containing a Gly574Ser mutation are not incorporated into the cartilage matrix of transgenic mice. Matrix Biology, 1997, 16, 93-103.	1.5	8
18	T cell immunodeficiency in a patient with 10p deletion syndrome. Journal of Pediatrics, 1989, 115, 330.	0.9	4

#	Article	IF	CITATIONS
19	Cell adaptation to activated FGFR3 includes Sprouty4 up regulation to inhibit the receptorâ€mediated ERKs activation from the endoplasmic reticulum. FEBS Letters, 2009, 583, 3254-3258.	1.3	4